PMID- 23869677
OWN - NLM
STAT- MEDLINE
DCOM- 20140121
LR  - 20181202
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 67
IP  - 8
DP  - 2013 Aug
TI  - Resource utilisation and quality of life following initiation of insulin detemir 
      in patients with type 2 diabetes mellitus.
PG  - 740-9
LID - 10.1111/ijcp.12133 [doi]
AB  - OBJECTIVE: Barriers to insulin initiation in type 2 diabetes mellitus (T2DM) 
      include fear of treatment complexity and perceived lack of time and resources by 
      primary care physicians. The SOLVE study investigated the effect of insulin 
      initiation on resource utilisation and patient quality of life. METHODS: SOLVE 
      was a 24-week cohort study in 10 countries evaluating the safety and 
      effectiveness of initiating once-daily insulin detemir in patients with T2DM. 
      Patient quality of life was assessed using the Insulin Treatment Appraisal Scale 
      (ITAS). RESULTS: A total of 14,611 (84%) patients completed the 24-week study. 
      During the study, HbA1c improved by 1.3 +/- 1.5%. The corresponding insulin dose 
      increased from 13 +/- 6 IU (0.16 +/- 0.09 IU/kg) at baseline, to 22 +/- 16 IU (0.27 +/- 
      0.17 IU/kg) at final visit. FlexPen was the preferred device (63%) for insulin 
      administration. The time taken to teach patients to self-inject and perform dose 
      self-adjustment was 15 +/- 13 min and 11 +/- 11 min, respectively. The quality of 
      life analysis included 6875 patients. The addition of insulin was associated with 
      an improvement in mean ITAS score [-3.5 (95% CI -3.8, -3.3), p < 0.001]. 
      Physicians reported the use or self-adjustment of insulin detemir as easy or very 
      easy in 79% of participants; and satisfaction with the level of glycaemic control 
      was reported for 74% of patients. CONCLUSIONS: Initiating basal insulin therapy 
      resulted in a substantial decrease in HbA1c and improved patients' perceptions of 
      insulin treatment.
CI  - (c) 2013 John Wiley & Sons Ltd.
FAU - Liebl, A
AU  - Liebl A
AD  - Center for Diabetes and Metabolism, m&i-Fachklinik Bad Heilbrunn, Bad Heilbrunn, 
      Germany. andreas.liebl@fachklinikbad-heilbrunn.de
FAU - Andersen, H
AU  - Andersen H
FAU - Svendsen, A L
AU  - Svendsen AL
FAU - Vora, J
AU  - Vora J
FAU - Yale, J-F
AU  - Yale JF
CN  - SOLVE Study Group
LA  - eng
SI  - ClinicalTrials.gov/NCT00740519
SI  - ClinicalTrials.gov/NCT00825643
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin, Long-Acting)
RN  - 4FT78T86XV (Insulin Detemir)
SB  - IM
MH  - Diabetes Mellitus, Type 2/*drug therapy/rehabilitation
MH  - Drug Administration Schedule
MH  - Female
MH  - Health Resources/*statistics & numerical data
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage/adverse effects
MH  - Injections, Intradermal
MH  - Insulin Detemir
MH  - Insulin, Long-Acting/*administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Patient Acceptance of Health Care/statistics & numerical data
MH  - Patient Satisfaction
MH  - *Quality of Life
EDAT- 2013/07/23 06:00
MHDA- 2014/01/22 06:00
CRDT- 2013/07/23 06:00
PHST- 2012/11/26 00:00 [received]
PHST- 2013/01/21 00:00 [accepted]
PHST- 2013/07/23 06:00 [entrez]
PHST- 2013/07/23 06:00 [pubmed]
PHST- 2014/01/22 06:00 [medline]
AID - 10.1111/ijcp.12133 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2013 Aug;67(8):740-9. doi: 10.1111/ijcp.12133.